Territorial Availability: Available through Bertin Technologies only in France
- Correlated keywords
- PKC alph beta gamma ? ? C 2 autoinhibited antiapoptotic proapoptotic posttraumatic
- Product Overview:
PKC? is an ?-type conventional isoform of the PKC family of serine/threonine protein kinases, which includes the conventional isoforms PKC?, -?, and -?, the novel isoforms PKC?, -?, -?, and -?, and the atypical isoforms PKC? and -?/?.{54650} PKC? is composed of an N-terminal regulatory domain containing a pseudosubstrate binding site, a C1 domain that binds the cofactor diacylglycerol (DAG), a C2 domain that binds the cofactor calcium, and a C-terminal domain containing an ATP-binding domain, substrate binding site, and catalytic domain. PKC? is ubiquitously expressed and localized to the cytoplasm in an auto-inhibited conformation until activated by calcium and DAG, which are both required for activation of the conventional PKC isoforms.{54650,54651} Activation of PKC? occurs via an allosteric and temporal mechanism during which it is translocated primarily to the plasma membrane where it phosphorylates a wide variety of substrates.{54650} PKC? is involved in the regulation of cell survival with anti- or pro-apoptotic effects and an increase or decrease in cell proliferation depending on the cellular context and cell type. It is also involved in cell differentiation and motility.{54651} Protein levels of PKC? are either increased or decreased in cancer cells, indicating a complex role in oncogenesis.{54652} Tumor levels of PKC? correlate positively to tumor grade and negatively to survival in patients with breast cancer.{54653} A SNP in PRKCA, which encodes PKC?, is associated with an increased risk of post-traumatic stress disorder (PTSD) in survivors of genocide.{54654} Cayman’s PKC? (human, recombinant) protein can be used for enzyme assay applications. This protein consists of 672 amino acids and has a calculated molecular weight of 102 kDa.
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.